Source: s3://data.kl3m.ai/documents/govinfo/USCOURTS/USCOURTS-caed-2_06-cv-01063/USCOURTS-caed-2_06-cv-01063-15/pdf.json

Nature of Suit Code: 365
Nature of Suit: Personal Injury - Product Liability
Cause of Action: 28:1441 Petition for Removal- Product Liability

---

UNITED STATES DISTRICT COURT 

EASTERN DISTRICT OF CALIFORNIA 

SACRAMENTO DIVISION 

TERRI S. O’NEAL, individually and as 

successor-in-interest to the Estate of 

BENJAMIN L. BRATT; BARRY M. BRATT, 

individually, 

 Plaintiffs, 

 vs. 

SMITHKLINE BEECHAM CORPORATION 

d/b/a GLAXOSMITHKLINE, a Pennsylvania 

Corporation; and DOES 1-50. 

 Defendants. 

Case No.: 2:06-CV-01063-FCD-DAD 

ORDER GRANTING DEFENDANT 

SMITHKLINE BEECHAM 

CORPORATION, D/B/A 

GLAXOSMITHKLINE'S REQUEST 

FOR CERTAIN EXHIBITS FILED BY 

PLAINTIFFS IN OPPOSITION TO 

GSK'S MOTION FOR SUMMARY 

JUDGMENT (FEDERAL 

PREEMPTION) TO BE SEALED 

 Defendant SmithKline Beecham Corporation, d/b/a GlaxoSmithKline ("GSK"), by 

counsel, having filed its Response to Plaintiffs' Ex Parte Application to Conditionally File Under 

Seal Documents and Exhibits in Support of Plaintiffs' Opposition to GSK's Motion for Summary 

Judgment (Federal Preemption), as certain exhibits filed by Plaintiffs contain sensitive and 

confidential commercial information, research, development information, and trade secrets 

regarding Paxil, and the Court, being duly advised, now finds that exhibits 2 (pages 410, 417-

420, 431 (lines 6-24), 464-466, 468 (line 25) -469); 3 (pages 161-165, 169); 4 (pages 168-170, 

184-186); 5 (pages 126 (lines 4-11, 18-24), 149 (lines 2-23), 165-166, 169-171, 174, 219 (lines 

14-24)); 6, 8 (pages 47 (line 1) - 48 (line 7), 109 (line 12) - 116 (line 11), 164 (line 19) - 167 

(line 15), 193 (lines 8-11), 195 (lines 17-23), 210 (lines 10-14), 218 (line 4) - 219 (line 10), 221 

(line 9) - 222 (line 10), 223 (line 8) - 224 (line 17), 241 (line 13) - 242 (line 10), 243 (line 14) - 

244 (line 12), 256 (line 20) - 259 (line 1), 263 (line 14) - 267 (line 2); 273 (line 1) - 274 (line 20), 

275 (line 8) - 278 (line 23), 286 (line 17) - 287 (line 12), 321 (line 17) - 322 (line 2), 322 (lines 

5-20), 325 (lines 18-24), 327 (line 17) - 329 (line 9), 330 (lines 2-6), 331 (lines 9-14)); 9 (pages 

70 (line 24) - 71 (line 7), 90 (lines 4-17), 99 (lines 2-14), 100 (line 22) - 101 (line 2)); 10 (pages 

Case 2:06-cv-01063-FCD-DAD Document 171 Filed 01/18/08 Page 1 of 2
165, 249 (lines 6-9); 11 (pages 62 (line 21) - 63 (line 9), 123 (line 20) - 124 (line 13), 126 (line 

14) - 127 (line 3), 128 (lines 22-24)); 16-18; 19 (pages 122 (lines 21-23), 123 (lines 1-2), 127 

(line 13) - 128 (line 1), 128 (lines 14-17), 131 (lines 8-14)); 21-25; 26 (only PAR008964009 

within exhibit); 28; 31; 40; 42-43; 59; 63; and 65 to the Declaration of George W. Murgatroyd 

III; exhibits 1 ( previously sealed pages 4-7, 9-13), and 2 (previously sealed in entirety) to the 

Declaration of Joseph Glenmullen, M.D.; and exhibit 1 to the Declaration of Roger Grimson, 

Ph.D, shall be SEALED. 

IT IS SO ORDERED. 

DATED: January 18, 2008 

Case 2:06-cv-01063-FCD-DAD Document 171 Filed 01/18/08 Page 2 of 2